Breast-Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application


  • This work was supported by the DFG (FOR630/BE 1264-9 and Graduate School BuildMoNa), EFRE (Grant 3370701481201), and the DAAD, which partially funded I.U.K. We thank all the technical assistants for their work.


original image

Selective, sensitive, and specific breast cancer diagnosis: Neuropeptide Y (NPY) and the Y1R-selective [Phe7, Pro34]NPY peptide were labeled with Re/99mTc and pre-clinically characterized using competition receptor binding and signal transduction assays, and also microscopic, metabolic-stability, rabbit body-uptake, and protein-binding studies. Selective uptake of the 99mTc(core)3+-(NαHis-ac)-labeled [Phe7, Pro34]NPY analogue in human breast-cancer patients was obtained by whole body scintimammography.